Zydus and MSN Launch First Generic Adempas in U.S.

Zydus Lifesciences Limited and MSN Laboratories Private Limited announced the launch of Riociguat Tablets in 0.5 mg, 1 mg, 1.5 mg, 2 mg, and 2.5 mg strengths in the United States on Monday, Oct. 5, 2026. According to a report by PR Newswire M&A, the companies represent the first to introduce a generic version of Adempas in the U.S. market. The product was developed and is manufactured by MSN, while Zydus handles commercialization.

Regulatory Status and Indication Details

The United States Food and Drug Administration approved Riociguat Tablets as a generic equivalent of Adempas across all five strengths. Riociguat functions as a soluble guanylate cyclase stimulator. It is indicated for adult patients with persistent or recurrent chronic thromboembolic pulmonary hypertension following surgical treatment, or inoperable chronic thromboembolic pulmonary hypertension, to improve exercise capacity and World Health Organization functional class. It is also indicated for adults with pulmonary arterial hypertension to improve exercise capacity, improve World Health Organization functional class, and delay clinical worsening.

Executive Commentary on Complex Generics

Dr. Sharvil Patel, managing director at Zydus Lifesciences Limited, noted that being first to market with generic riociguat serves as a milestone for the company and for patients. Patel stated that the rollout reflects the strength of the company's complex-generics pipeline and the execution of day-one launches in specialty categories. Dr. MSN Reddy, founder and chairman and managing director of MSN Laboratories, described riociguat as a technically demanding molecule. Reddy added that bringing the first generic to the U.S. demonstrates the depth of the company's integrated active pharmaceutical ingredient and formulation research and development alongside its manufacturing scale, similar to how Benchmark's full partnership to address breakout startup trends at TechCrunch Disrupt 2026 highlights specialized operational scaling.

Global Sales and Market Dynamics

Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension are rare, progressive, and life-threatening conditions where patients typically remain on therapy for life. Prior to this partnership, riociguat was available in the United States only as the branded product. While sales of riociguat are not reported by IQVIA, Bayer's Annual Report 2025 noted that global sales of Adempas reached approximately EUR 745 million, or approximately USD 850 million, in 2025.

Corporate Background and Manufacturing Footprint

Zydus Lifesciences Ltd., with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 30,000 people worldwide, including 1,500 scientists engaged in research and development, and is driven by its mission to unlock new possibilities in life sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries. Over the last decade, Zydus has introduced several innovative, first-in class products in the market for treating unmet healthcare needs with vaccines, therapeutics, biologicals, and New Chemical Entities.

MSN Laboratories Group operates 25 manufacturing facilities across India and the USA, backed by a unified research and development ecosystem spanning active pharmaceutical ingredients and finished dosage development. MSN has filed over 1,000 patents globally and submitted more than 200 abbreviated new drug applications, much like broader corporate scaling seen when Capstone Partners releases 2026 middle market survey showing CEOs adapt to volatility across industries. MSN maintains a portfolio of more than 550 active pharmaceutical ingredients and over 400 finished dosage forms across 35 therapeutic areas, serving more than 50 million patients in over 100 countries. Adempas is a registered trademark of Bayer, and all other trademarks are the property of their respective owners.